Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Control of EGF receptor activation in Drosophila.

Wasserman JD, Freeman M.

Trends Cell Biol. 1997 Nov;7(11):431-6.

PMID:
17709000
2.

Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells.

Neve RM, Sutterl├╝ty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE.

Oncogene. 2000 Mar 23;19(13):1647-56.

3.
4.

Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells.

Darcy KM, Zangani D, Wohlhueter AL, Huang RY, Vaughan MM, Russell JA, Ip MM.

J Histochem Cytochem. 2000 Jan;48(1):63-80.

PMID:
10653587
5.

ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases.

Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL.

J Cell Biol. 2000 Jan 24;148(2):385-97.

6.

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.

Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y.

Mol Cell. 1999 Dec;4(6):1029-40.

7.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ.

J Clin Oncol. 1999 Sep;17(9):2639-48.

PMID:
10561337
8.

Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7.

Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H, Yoshimura A, Baron R.

J Biol Chem. 1999 Oct 29;274(44):31707-12.

9.

The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.

Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC.

Science. 1999 Oct 8;286(5438):309-12.

10.
11.

The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor.

Chattopadhyay A, Vecchi M, Ji Qs, Mernaugh R, Carpenter G.

J Biol Chem. 1999 Sep 10;274(37):26091-7.

12.

Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways.

Carpenter G.

J Cell Biol. 1999 Aug 23;146(4):697-702. Review. No abstract available.

13.
14.

Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development.

Morris JK, Lin W, Hauser C, Marchuk Y, Getman D, Lee KF.

Neuron. 1999 Jun;23(2):273-83.

15.

CDK inhibitors: positive and negative regulators of G1-phase progression.

Sherr CJ, Roberts JM.

Genes Dev. 1999 Jun 15;13(12):1501-12. Review. No abstract available.

17.

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.

Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE.

J Biol Chem. 1999 Jun 11;274(24):17209-18.

18.

Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase.

Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M.

Oncogene. 1999 Apr 22;18(16):2607-15.

19.

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.

Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y.

Oncogene. 1999 Apr 29;18(17):2681-9.

20.

Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development.

Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC.

Development. 1999 Jun;126(12):2739-50.

Supplemental Content

Support Center